{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:33:58Z","timestamp":1793918038976,"version":"4.8.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010097","name":"China Association for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Primary ovarian mesothelioma (POM) is a rare malignant tumor with poor prognosis. Although anaplastic lymphoma kinase gene (ALK) double-fusion partners have been found in various tumors, it is rarely reported in mesothelioma. In this article, we describe the coexistence of a novel STRN-ALK, neurobeachin (NBEA)-ALK double-fusion in a patient with primary ovarian mesothelioma. A 30-year-old woman was found to have pelvic masses for more than a year. Color Doppler ultrasound showed mixed mass in the left ovary and multiple solid masses in the right ovary. the patient underwent laparoscopic surgery, including total hysterectomy, bilateral salpingo-oopherectomy, pelvic lymph node and abdominal aortic lymph node resection, omentum resection and abdominal focus resection. Pathologic examination revealed bilateral ovarian malignant mesothelioma and no evidence of malignancy in the resected bilateral round\/broad ligaments, bilateral parametrial tissues, vaginal stump, bilateral fallopian tubes, pelvic and paraaortic lymph nodes. Immunohistochemistry showed that it was positive for Calretinin, VIM, WT1, PAX8, mesothelin, CK5\/6, PCK, CK7, MLH1, PMS2, MSH2, MSH6, weakly positive for BAP1, while being negative for Napsin A, P504S, CEA, D2-40, GATA3. The sequencing analysis identified STRN-ALK (intron3:intron19) and NBEA-ALK (intron1:intron16) double-ALK fusion. To the best of our knowledge, this is the first report that a novel NBEA-ALK and EML4-ALK coexist in one patient with POM. The patient has completed 6 cycles of continuous chemotherapy and is in stable condition. Whether ALK inhibitors can bring promising benefits to POM patients in the future deserves further study.<\/jats:p>","DOI":"10.3389\/fonc.2023.1156329","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:23:50Z","timestamp":1682051030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1066896910370880","article-title":"Malignant mesothelioma mimicking ovarian cancer","volume":"18","author":"Merino","year":"2010","journal-title":"Int J Surg Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1983.tb02242.x","article-title":"Papillary mesothelioma of ovary","volume":"7","author":"Addis","year":"1983","journal-title":"Histopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002795","article-title":"18F-FDG PET\/CT findings of ovarian mesothelioma: a case study","volume":"44","author":"Sun","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.38.92.24462","article-title":"M\u00e9soth\u00e9liome malin de l\u00b4ovaire: \u00e0 propos d\u00b4un cas [Malignant mesothelioma of the ovary: a case report]","volume":"38","author":"Ouafki","year":"2021","journal-title":"Pan Afr Med J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199609000-00004","article-title":"Malignant mesotheliomas presenting as ovarian masses. a report of nine cases, including two primary ovarian mesotheliomas","volume":"20","author":"Clement","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092278","article-title":"Primary ovarian mesothelioma: a case series with electron microscopy examination and review of the literature","volume":"13","author":"Vimercati","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","article-title":"The role of the ALK receptor in cancer biology","author":"Hallberg","year":"2016","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100618","article-title":"Therapeutic advances of rare ALK fusions in non-small cell lung cancer","volume":"29","author":"Xiang","year":"2022","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2324-z","article-title":"Identification of a prognostic 5-gene expression signature for gastric cancer","volume":"143","author":"Hou","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.015","article-title":"Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: a case report","volume":"162","author":"Liang","year":"2021","journal-title":"Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.11.008","article-title":"Association of directors of anatomic and surgical pathology. recommendations for the reporting of pleural mesothelioma","volume":"38","author":"Butnor","year":"2007","journal-title":"Hum Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33433","article-title":"Malignant mesothelioma: advances in immune checkpoint inhibitor and mesothelin-targeted therapies","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2019.1598374","article-title":"Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma","volume":"16","author":"Chia","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100125","article-title":"STRN-ALK, A novel in-frame fusion with response to alectinib","volume":"2","author":"Nagasaka","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","article-title":"The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)","volume":"17","author":"Golding","year":"2018","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12613","article-title":"ALK-rearrangement in non-small-cell lung cancer (NSCLC)","volume":"9","author":"Du","year":"2018","journal-title":"Thorac Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2017.04.003","article-title":"A rare STRN-ALK fusion in lung adenocarcinoma identified using next-generation sequencing-based circulating tumor DNA profiling exhibits excellent response to crizotinib","volume":"1","author":"Yang","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001656","article-title":"Pediatric mesothelioma with ALK fusions: a molecular and pathologic study of 5 cases","volume":"45","author":"Argani","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":":1\u20136","DOI":"10.1200\/PO.19.00048","article-title":"STRN-ALK Rearranged malignant peritoneal mesothelioma with dramatic response following ceritinib treatment","volume":"3","author":"R\u00fcschoff","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101027","article-title":"STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - functional testing of 527 cancer drugs in patient-derived cancer cells","volume":"14","author":"Murum\u00e4gi","year":"2021","journal-title":"Transl Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":":1507\u201313","DOI":"10.1200\/PO.21.00184","article-title":"STRN-ALK Fusion in a case of malignant peritoneal mesothelioma: mixed response to crizotinib, mode of resistance, and brigatinib sequential therapy","volume":"5","author":"Gerthofer","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13714","article-title":"A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20: a case report and literature review","volume":"26","author":"Miyagawa","year":"2021","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s003359901154","article-title":"The neurobeachin gene (Nbea) identifies a new region of homology between mouse central chromosome 3 and human chromosome 13q13","volume":"10","author":"Gilbert","year":"1999","journal-title":"Mamm Genome"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2018.08.020","article-title":"Genome-wide association study for tumour stage, grade, size, and age at diagnosis of non-muscle-invasive bladder cancer","volume":"2","author":"Lipunova","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2014.09.009","article-title":"Prognostic significance of decreased expression of six large common fragile site genes in oropharyngeal squamous cell carcinomas","volume":"7","author":"Gao","year":"2014","journal-title":"Transl Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1156329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:23:53Z","timestamp":1682051033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1156329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":33,"alternative-id":["10.3389\/fonc.2023.1156329"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1156329","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1156329"}}